

Flash Note: Acromec Limited

Date: 20 March 2019

Won contract of S\$7.6 million for Mechanical & Electrical works in the construction of a poultry farm for Chew's Agriculture

Acromec Limited ("**Acromec**", or the "**Company**") and together with its subsidiary, the "**Group**") announced that it has been appointed as the nominated sub-contractor for the Mechanical & Electrical ("**M&E**") works for Chew's Agriculture Pte. Ltd ("**Chew's**") new poultry farm at Neo Tiew Road, Singapore. The contract has a value of S\$7.6 million with a scope of work that encompasses the installation of the air-conditioning and ventilation, plumbing and sanitary, and electrical and fire-protection systems of the farm. All works, which include testing and commissioning, is to be completed by 31 December 2019.

Contract win is an extension of earlier signed binding letter of intent with Chew's to build, own and operate a biomass-to-energy power plant

The farm's M&E construction contract ties in and is in addition to the letter of intent ("**LOI**") signed by the Group's 80%-owned subsidiary, Acropower Pte. Ltd., with Chew's on 4 December 2018 to build, own and operate a biomass-to-energy power plant. The subsequent extension of the LOI to 4 April 2019, with an eventual view to the execution of a definitive agreement, was announced on 6 March 2019. The power plant will also be situated on the poultry farm and will treat and convert chicken manure from the farm into electricity, which will then be sold back to the farm for its consumption.

With this contract win, Acromec's order book now stands at approximately S\$20.0 million. This contract is expected to contribute positively to the earnings per share and net tangible assets per share of the Group for the financial year ending 30 September 2019.

About Acromec Limited

Acromec is an established specialist engineering services provider with more than 20 years of experience in the field of controlled environments. The Group has over the years acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

Acromec's business is divided into two main business segments: (i) Engineering, procurement and construction services, specialising in architectural, and mechanical, electrical and process works within controlled environments; and (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure.

The Group mainly serves the healthcare, pharmaceutical, biomedical science, research and academia, and electronics sectors. Acromec counts amongst its customers, hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

Analyst

Terence Chua
+65 6232 3236

tchua@saccapital.com.sg

DISCLAIMERS AND DISCLOSURES

This report has been prepared and distributed by SAC Advisors Private Limited (“**SAC Advisors**”) which is a holder of a capital markets services licence and an exempt financial adviser in Singapore. SAC Advisors is a wholly-owned subsidiary of SAC Capital Private Limited (“**SAC Capital**”) which is also a capital markets services licensee.

This report has been prepared for the purpose of general circulation. In the preparation of this report, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities.

This report is confidential and is meant only for the consumption of targeted persons. The information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Advisors. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

While SAC Advisors has exercised reasonable care to ensure that the facts stated herein are accurate, SAC Advisors makes no representation as to the accuracy or completeness of such information and SAC Advisors accepts no liability whatsoever for any loss or damage arising from the use of or reliance of the information herein.

SAC Advisors, SAC Capital and their associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance related services for the company whose securities are covered in the report. SAC Advisors and its related companies may from time to time perform advisory services, or solicit such advisory service from the entity mentioned in this report (“**Other Services**”). However, the research professionals involved in the preparation of this report have not and will not participate in the solicitation of such business. This report is therefore classified as a non-independent report.

As of the date of this report, SAC Advisors and its associates, including SAC Capital, do not have proprietary positions with Acromec Limited, except for:

Party	Quantum of position
Nil	Nil

As of the date of this report, SAC Advisors and its associates, including SAC Capital, do not have any business relations with the subject company within the past 12 months, except for:

Company	Nature of business relation	Date of business relation
Acromec Limited	Continuing Sponsor	Ongoing

As of the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

Analyst name	Quantum of position
Nil	Nil

ANALYST CERTIFICATION/REGULATION AC

As noted above, research analyst(s) of SAC Advisors who produced this report hereby certify that

- (i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);
- (ii) The report was produced independently by him/her;
- (iii) He/she does not on behalf of SAC Advisors or SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and
- (iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.